Selenium and bladder cancer risk: A meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 9, 2010, Pages 2407-2415

  Amaral, André F S ^a   Cantor, Kenneth P ^b   Silverman, Debra T ^c   Malats, Núria ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b KP Cantor Environmental LLC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SELENIUM;

AGE; ARTICLE; BELGIUM; BLADDER CANCER; BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; GENDER; HUMAN; META ANALYSIS; NETHERLANDS; PRIORITY JOURNAL; PUBLICATION; RISK; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; TOENAIL ONYCHOMYCOSIS; UNITED STATES;

FEMALE; HUMANS; MALE; NAILS; RISK FACTORS; SELENIUM; URINARY BLADDER NEOPLASMS;

EID: 77956518107     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0544     Document Type: Article

References (40)

1. Silverman D, Devesa S, Moore L, Rothman N. Bladder cancer. In: Schottenfeld D, Fraumeni J, Jr., editors. Cancer epidemiology and prevention. 3rd ed. New York (NY): Oxford University Press; 2006, p. 1101-27.
2. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366:649-59.
3. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 2007;25:285-95.
4. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1-40.
5. Navarro Silvera SA, Rohan TE. Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 2007;18: 7-27.
6. Bardia A, Tleyjeh IM, Cerhan JR, et al. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc 2008;83:23-34.
7. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev 2008:CD004183.
8. Zhuo H, Smith AH, Steinmaus C. Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev 2004;13:771-8. (Pubitemid 38737866)
9. Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control 2005;16:1125-31. (Pubitemid 41356011)
10. Meyer F, Galan P, Douville P, et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 2005;116:182-6. (Pubitemid 40967253)
11. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12.
12. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301: 39-51.
13. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, Guallar E. Selenium and coronary heart disease: a meta-analysis. Am J Clin Nutr 2006;84:762-73. (Pubitemid 44715658)
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
15. Knekt P, Aromaa A, Maatela J, et al. Serum micronutrients and risk of cancers of low incidence in Finland. Am J Epidemiol 1991;134: 356-61.
16. Nomura A, Heilbrun LK, Morris JS, Stemmermann GN. Serum selenium and the risk of cancer, by specific sites: case-control analysis of prospective data. J Natl Cancer Inst 1987;79:103-8. (Pubitemid 17102555)
17. Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, α-tocopherol, β-carotene, retinol, and subsequent bladder cancer. Cancer Res 1989;49:6144-8.
18. Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol 2006;13:1180-4. (Pubitemid 44410906)
19. Michaud DS, De Vivo I, Morris JS, Giovannucci E. Toenail selenium concentrations and bladder cancer risk in women and men. Br J Cancer 2005;93:804-6. (Pubitemid 41486441)
20. Michaud DS, Hartman TJ, Taylor PR, et al. No Association between toenail selenium levels and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1505-6.
21. Zeegers MP, Goldbohm RA, Bode P, van den Brandt PA. Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1292-7. (Pubitemid 35340363)
22. Wallace K, Kelsey KT, Schned A, Morris JS, Andrew AS, Karagas MR. Selenium and risk of bladder cancer: a population-based case-control study. Cancer Prev Res 2009;2:70-3.
23. Clark LC, Combs GF, Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
24. Longnecker MP, Taylor PR, Levander OA, et al. Selenium in diet, blood, and toenails in relation to human health in a seleniferous area. Am J Clin Nutr 1991;53:1288-94.
25. Satia J, King I, Morris J, Stratton K, White E. Toenail and plasma levels as biomarkers of selenium exposure. Ann Epidemiol 2006;16: 53-8. (Pubitemid 41783889)
26. Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr 2004;58:391-402.
27. Murawaki Y, Tsuchiya H, Kanbe T, et al. Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett 2008;259:218-30. (Pubitemid 350258671)
28. Jackson MI, Combs GF, Jr. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 2008;11:718-26.
29. Fowler BA, Whittaker MH, Lipsky M, Wang G, Chen XQ. Oxidative stress induced by lead, cadmium and arsenic mixtures: 30-day, 90-day, and 180-day drinking water studies in rats: an overview. Biometals 2004;17:567-8. (Pubitemid 41214269)
30. Schrauzer GN. Anticarcinogenic effects of selenium. Cell Mol Life Sci 2000;57:1864-73.
31. Smith ML, Lancia JK, Mercer TI, Ip C. Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res 2004; 24:1401-8. (Pubitemid 38954655)
32. Fischer JL, Lancia JK, Mathur A, Smith ML. Selenium protection from DNA damage involves a Ref1/p53/Brca1 protein complex. Anticancer Res 2006;26:899-904.
33. SlotnickMJ, Nriagu JO. Validity of human nails as a biomarker of arsenic and selenium exposure: A review. Environ Res 2006;102:125-39.
34. Arnaud J, Bertrais S, Roussel AM, et al. Serum selenium determinants in French adults: the SU.VI.M.AX study. Br J Nutr 2006;95:313-20.
35. Longnecker MP, Stram DO, Taylor PR, et al. Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiology 1996;7:384-90.
36. Garland M, Morris JS, Rosner BA, et al. Toenail trace element levels as biomarkers: reproducibility over a 6-year period. Cancer Epidemiol Biomarkers Prev 1993;2:493-7.
37. Sanchez C, Lopez-Jurado M, Aranda P, Llopis J. Plasma levels of copper, manganese and selenium in an adult population in southern Spain: Influence of age, obesity and lifestyle factors. Sci Total Environ 2010;408:1014-20.
38. Swanson C, Longnecker M, Veillon C, et al. Selenium intake, age, gender, and smoking in relation to indices of selenium status of adults residing in a seleniferous area. Am J Clin Nutr 1990;52: 858-62. (Pubitemid 20380804)
39. Rodriguez Rodriguez EM, Sanz Alaejos MT, Diaz Romero C. Urinary selenium status of healthy people. Eur J Clin Chem Clin Biochem 1995;33:127-33.
40. Patterson B, Veillon CC, Taylor P, Patterson K, Levander OA. Selenium metabolism in humans differs by gender: results from a stable isotope tracer study. FASEB J 2001;15:A969.